Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer

Early Phase 1

Active, not recruiting

• Conditions: Malignant Solid Neoplasm; Hematopoietic and Lymphoid System Neoplasm
• Interventions: Procedure: Biospecimen Collection; Genetic: Genetic Testing for Cancer Risk; Procedure: Liquid Biopsy; Procedure: Magnetic Resonance Imaging of the Whole Body without Contrast; Other: Survey Administration

• Registration Number: NCT05868486
• Lead Sponsor: City of Hope Medical Center

Brief Summary

This study evaluates patient acceptability of whole body magnetic resonance imaging (WBM) and liquid biopsies (LB) in detecting early stage cancer in patients with a strong family history of cancer. Collecting family history and testing for genes passed on from parent to child (germline testing) can be used to predict the likelihood of a patient developing cancer. Currently, detection of early cancers focuses on screening specific organ systems such as breast and colon cancer. Magnetic resonance imaging (MRI) uses a large magnet and radio waves to look at organs and structures inside the body. Health care professionals use MRI scans to diagnose a variety of conditions, from torn ligaments to cancer. Liquid biopsy is test that analyzes blood samples to determine if cancer cells are present. This study may help researchers determine the feasibility of WBM and liquid biopsies to detect early stage cancer in patients that have a strong family history of cancer.

Detailed Description

PRIMARY OBJECTIVE:

I. To assess the acceptability of the approach of LB and WBM.

SECONDARY OBJECTIVES:

I. Determine the prevalence of WBM findings requiring additional imaging or invasive testing.

II. Determine the effect of germline testing, LB, and WBM on psychological distress and health-related quality of life (HR-QOL) at 6 months after testing compared with baseline.

EXPLORATORY OBJECTIVE:

I. Determine correlation between high-risk LB findings and cancer detected on WBM.

OUTLINE: This is an observational study.

Patients undergo WBM without contrast, blood sample collection for liquid biopsy, and complete surveys on study. Germline testing may also be performed on blood sample collected as standard of care or using the Precision Medicine protocol (Institutional Review Board \[IRB\] 96144).

Study Timeline

• Study Start: 2022-05-20
• Study First Submitted: 2023-03-29
• Study First Submitted QC: 2023-05-19
• Study First Posted: 2023-05-22
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-28
• Last Update Posted: 2025-01-29
• Primary Completion: 2025-07-20
• Study Completion: 2025-07-20

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Age >= 50 years, or age within 10 years of first degree relative with cancer at age of diagnosis (as long as age is >= 18)
• Have a strong family history of cancer ( >= 2 first-degree relatives with cancer, one first and second degree relative with cancer in one lineage (side of family), or at least three first or second degree relatives with cancer in one lineage (side of the family). Non-melanoma skin cancer excluded from family history eligibility
• Have a family history of early-onset cancer (age >40) in at least one first-degree relative
• Willing to have 50 mL of blood (approximately 3.5 tablespoons) drawn (40 ml if germline testing already performed)
• Able to undergo MRI (no implants, metal, or claustrophobia that would preclude MRI)
• Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer
• Positron emission tomography/computed tomography (PET/CT) or other whole body imaging modality (including combination of CT chest and abdomen) within 3 years
• No signs/symptoms of possible cancer (e.g. hemoptysis, breast mass, blood per rectum, unexplained weight loss)
• Willing to undergo standard of care genetic counseling and germline testing, or has already undergone genetic counseling and germline testing
• Documented informed consent of the participant

Exclusion Criteria

• Unable to provide informed consent
• Contraindications to MRI (implants, metal, or claustrophobia that would preclude MRI)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Whole Body MRI and Liquid Biopsy	Liquid Biopsy	Patients undergo WBM without contrast and blood sample collection for liquid biopsy
Whole Body MRI and Liquid Biopsy	Biospecimen Collection	Patients undergo WBM without contrast and blood sample collection for liquid biopsy
Whole Body MRI and Liquid Biopsy	Genetic Testing for Cancer Risk	Patients undergo WBM without contrast and blood sample collection for liquid biopsy
Whole Body MRI and Liquid Biopsy	Survey Administration	Patients undergo WBM without contrast and blood sample collection for liquid biopsy
Whole Body MRI and Liquid Biopsy	Magnetic Resonance Imaging of the Whole Body without Contrast	Patients undergo WBM without contrast and blood sample collection for liquid biopsy

Primary Outcome Measures

Name	Time	Method
Acceptability of germline testing, liquid biopsy and whole body magnetic resonance imaging (WBM)	Up to 6 months after WBM	Acceptability, as measured by the survey question "How satisfied are you with the research study overall?" and is defined as a score of 4 ("moderately acceptable) or 5 ("highly acceptable").

Secondary Outcome Measures

Name	Time	Method
Psychological distress (Germline testing)A	Up to 6 months after WBM	The effect of germline testing on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing.
Psychological distress (WBM)A	Up to 6 months after WBM	The effect of Whole Body MRI on Psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing.
Prevalence of WBM findings requiring additional imaging or invasive testing	Up to 6 months after WBM	Prevalence of WBM findings requiring additional imaging or invasive testing, described as a per participant percentage.
Psychological distress (Germline testing)B	Up to 6 months after WBM	The effect of germline testing on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing.
Psychological distress (Liquid Biopsy)B	Up to 6 months after WBM	The effect of LB on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing.
Psychological distress (WBM)B	Up to 6 months after WBM	The effect of Whole Body MRI on Psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing.
Psychological distress (Liquid Biopsy)A	Up to 6 months after WBM	The effect of LB on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing.
Health Related Quality of Life (HRQOL/Germline)	Up to 6 months after WBM	The effect of germline testing on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing.
Health Related Quality of Life (HRQOL/LB)	Up to 6 months after WBM	The effect of LB on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing.
Health Related Quality of Life (HRQOL/WBM)	Up to 6 months after WBM	The effect of WBM on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing.

Trial Locations

Locations (1)

City of Hope Medical Center; 🇺🇸 Duarte, California, United States